COMMUNIQUÉS West-GlobeNewswire

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
25/01/2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a [...]
Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.
25/01/2024
Grants, New Mexico, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) today announced the agreement to purchase assets from C2 Wellness Corporation. (“C2”), a Wyoming registered company with an [...]
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
25/01/2024
WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical [...]
NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
25/01/2024
Project to benefit from Scorpius’ comprehensive services in process development, bioanalysis, and cGMP manufacturing DURHAM, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“ [...]
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
25/01/2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing [...]
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
25/01/2024
Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration NGC-Cap was better tolerated with positive preliminary [...]
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
25/01/2024
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced [...]
Evaxion développe de nouveaux vaccins personnalisés contre le cancer basés sur une nouvelle source inexploitée de cibles découvertes par l’IA
25/01/2024
Des vaccins sur mesure : avec la découverte de ces nouveaux types de cibles vaccinales contre le cancer grâce à AI-Immunology™, la conception de solutions vaccinales personnalisées et de précision devient réalisable et [...]
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
25/01/2024
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis [...]
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
25/01/2024
CUPERTINO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
25/01/2024
CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
25/01/2024
SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ocular [...]
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
25/01/2024
Company eliminates three executive officer roles and appoints new Executive Leadership team SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated [...]
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
25/01/2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“ [...]
Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
25/01/2024
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Cancers from a team of cancer researchers primarily at the NCI-Designated Cancer Center, [...]
SS Innovations Partners with India’s Leading Medical Equipment Supplier, Medikabazaar
25/01/2024
Collaboration to facilitate sales of the SSi Mantra Surgical Robotic System to hospitals and medical facilities across India FORT LAUDERDALE, Fla., Jan. 25, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. ( [...]
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
25/01/2024
New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac Function and Stabilization of Fibrosis SOUTH SAN [...]
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
25/01/2024
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for eligible patients. ANN [...]
ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review
25/01/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the European regulatory filing for ACARIZAX ® (house dust mite sublingual immunotherapy tablet) in young children has been accepted for review by the relevant [...]

Pages